Different protective actions of losartan and tempol on the renal inflammatory response to acute sodium overload

J Cell Physiol. 2010 Jul;224(1):41-8. doi: 10.1002/jcp.22087.

Abstract

The aim of this work was to study the role of local intrarenal angiotensin II (Ang II) and the oxidative stress in the up-regulation of pro-inflammatory cytokines expression observed in rats submitted to an acute sodium overload. Sprague-Dawley rats were infused for 2 h with isotonic saline solution (Control group) and with hypertonic saline solution alone (Na group), plus the AT1 receptor antagonist losartan (10 mg kg(-1) in bolus) (Na-Los group), or plus the superoxide dismutase mimetic tempol (0.5 mg min(-1) kg(-1)) (Na-Temp group). Mean arterial pressure, glomerular filtration rate, and fractional sodium excretion (FE(Na)) were measured. Ang II, NF-kappaB, hypoxia inducible factor-1 alpha (HIF-1 alpha), transforming growth factor beta1 (TGF-beta1), smooth muscle actin (alpha-SMA), endothelial nitric oxide synthase (eNOS), and RANTES renal expression was evaluated by immunohistochemistry. Ang II, NF-kappaB, and TGF-beta1 and RANTES early inflammatory markers were overexpressed in Na group, accompanied by enhanced HIF-1 alpha immunostaining, lower eNOS expression, and unmodified alpha-SMA. Losartan and tempol increased FE(Na) in sodium overload group. Although losartan reduced Ang II and NF-kappaB staining and increased eNOS expression, it did not restore HIF-1 alpha expression and did not prevent inflammation. Conversely, tempol increased eNOS and natriuresis, restored HIF-1 alpha expression, and prevented inflammation. Early inflammatory markers observed in rats with acute sodium overload is associated with the imbalance between HIF-1 alpha and eNOS expression. While both losartan and tempol increased natriuresis and eNOS expression, only tempol was effective in restoring HIF-1 alpha expression and down-regulating TGF-beta1 and RANTES expression. The protective role of tempol, but not of losartan, in the inflammatory response may be associated with its greater antioxidant effects.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Actins / metabolism
  • Angiotensin II / metabolism
  • Angiotensin II Type 1 Receptor Blockers / pharmacology*
  • Animals
  • Antioxidants / pharmacology*
  • Blood Pressure / drug effects
  • Chemokine CCL5 / metabolism
  • Cyclic N-Oxides / pharmacology*
  • Disease Models, Animal
  • Glomerular Filtration Rate / drug effects
  • Hypoxia-Inducible Factor 1, alpha Subunit / metabolism
  • Inflammation Mediators / metabolism*
  • Kidney / drug effects*
  • Kidney / metabolism
  • Kidney / physiopathology
  • Losartan / pharmacology*
  • Male
  • NF-kappa B / metabolism
  • Natriuresis / drug effects
  • Nephritis / etiology
  • Nephritis / metabolism
  • Nephritis / physiopathology
  • Nephritis / prevention & control*
  • Nitric Oxide Synthase Type III / metabolism
  • Oxidative Stress / drug effects*
  • Rats
  • Rats, Sprague-Dawley
  • Saline Solution, Hypertonic
  • Spin Labels
  • Time Factors
  • Transforming Growth Factor beta1 / metabolism
  • Water-Electrolyte Imbalance / drug therapy*
  • Water-Electrolyte Imbalance / etiology
  • Water-Electrolyte Imbalance / metabolism
  • Water-Electrolyte Imbalance / physiopathology

Substances

  • Actins
  • Angiotensin II Type 1 Receptor Blockers
  • Antioxidants
  • Chemokine CCL5
  • Cyclic N-Oxides
  • Hif1a protein, rat
  • Hypoxia-Inducible Factor 1, alpha Subunit
  • Inflammation Mediators
  • NF-kappa B
  • Saline Solution, Hypertonic
  • Spin Labels
  • Transforming Growth Factor beta1
  • smooth muscle actin, rat
  • Angiotensin II
  • Nitric Oxide Synthase Type III
  • Nos3 protein, rat
  • Losartan
  • tempol